Please ensure Javascript is enabled for purposes of website accessibility
Skip to main content
Poised to address unmet need in neuromuscular diseases and
positioned for growth

Press Releases

Press Releases

2026 2025 2024 2023 2022 2021 2020 2019 all

May 12, 2020

Dyne Therapeutics Demonstrates FORCE TM Platform’s Potential to Deliver Potent Exon-Skipping Molecules Directly to Muscle to Treat Duchenne Muscular Dystrophy

May 11, 2020

Dyne Therapeutics Announces Appointment of Debra Feldman as Vice President, Head of Regulatory

April 23, 2020

Dyne Therapeutics Appoints David Lubner to Board of Directors

March 31, 2020

Dyne Therapeutics Announces Equity Investment from CureDuchenne Ventures to Support Pioneering Approach to Restoring Muscle Health in DMD

February 6, 2020

Dyne Therapeutics Expands Leadership Team with Key Hires

January 13, 2020

Dyne Therapeutics Announces Appointment of Molly White as Vice President, Medical Communications and Advocacy

October 1, 2019

Dyne Therapeutics Announces Appointment of Joshua Brumm as President and Chief Executive Officer

September 23, 2019

Dyne Therapeutics Announces Support for ReSolve Natural History Study of Patients with Facioscapulohumeral Muscular Dystrophy (FSHD)

August 19, 2019

Dyne Therapeutics Expands Board of Directors with Appointment of Lawrence Klein

June 28, 2019

Dyne Therapeutics Appoints Catherine Stehman-Breen to its Board of Directors

June 17, 2019

Dyne Therapeutics Announces Support for END-DM1 Natural History Study of Patients with Myotonic Dystrophy Type 1 (DM1)

June 13, 2019

Dyne Therapeutics Presents Nonhuman Primate Proof of Concept Data on FORCE™ Therapeutic Platform at International Myotonic Dystrophy Consortium Meeting (IDMC-12)

April 3, 2019

Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle Diseases
Displaying 141 - 153 of 153
Stay in touch

You are now leaving 
the Dyne Therapeutics corporate website

Continue